These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38879249)

  • 1. Genericisation in cost-effectiveness analysis of cystic fibrosis medicines.
    Beattie A; Moore A; Ramagopalan SV
    Lancet; 2024 Jun; 403(10444):2591-2592. PubMed ID: 38879249
    [No Abstract]   [Full Text] [Related]  

  • 2. Precision Medicine: At What Price?
    Ferkol T; Quinton P
    Am J Respir Crit Care Med; 2015 Sep; 192(6):658-9. PubMed ID: 26207804
    [No Abstract]   [Full Text] [Related]  

  • 3. Cystic fibrosis drug is not cost effective, says NICE.
    Gulland A
    BMJ; 2016 Jun; 353():i3409. PubMed ID: 27325384
    [No Abstract]   [Full Text] [Related]  

  • 4. Lumacaftor/ivacaftor (Orkambi) for cystic fibrosis.
    Med Lett Drugs Ther; 2016 Mar; 58(1491):41-2. PubMed ID: 27027688
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost-Effectiveness and Budget Impact of Lumacaftor/Ivacaftor in the Treatment of Cystic Fibrosis.
    Vadagam P; Kamal KM; Covvey JR; Giannetti V; Mukherjee K
    J Manag Care Spec Pharm; 2018 Oct; 24(10):987-997. PubMed ID: 30247102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Orphan Drug Pricing and Costs: A Case Study of Kalydeco and Orkambi.
    Hollis A
    Healthc Policy; 2019 Aug; 15(1):70-80. PubMed ID: 31629457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Orkambi's Slick Unveiling Puts Insurers in a Bind.
    Silverman E
    Manag Care; 2015 Aug; 24(8):16-7. PubMed ID: 26399136
    [No Abstract]   [Full Text] [Related]  

  • 8. The effectiveness and value of novel treatments for cystic fibrosis.
    Tice JA; Kuntz KM; Wherry K; Seidner M; Rind DM; Pearson SD
    J Manag Care Spec Pharm; 2021 Feb; 27(2):276-280. PubMed ID: 33506736
    [No Abstract]   [Full Text] [Related]  

  • 9. Adherence to lumacaftor-ivacaftor therapy in patients with cystic fibrosis in France.
    Olivereau L; Nave V; Garcia S; Perceval M; Rabilloud M; Durieu I; Reynaud Q
    J Cyst Fibros; 2020 May; 19(3):402-406. PubMed ID: 31902692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CFTR modulators: transformative therapies for cystic fibrosis.
    Dwight M; Marshall B
    J Manag Care Spec Pharm; 2021 Feb; 27(2):281-284. PubMed ID: 33506726
    [No Abstract]   [Full Text] [Related]  

  • 11. Treating Specific Variants Causing Cystic Fibrosis.
    Cutting GR
    JAMA; 2017 Dec; 318(21):2130-2131. PubMed ID: 29209709
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacokinetic Enhancement of Elexacaftor/Tezacaftor/Ivacaftor for Cystic Fibrosis: A Cost Reduction Strategy to Address Global Disparities in Access.
    Hong E; Zampoli M; Beringer PM
    Clin Pharmacol Ther; 2024 Jun; 115(6):1204-1207. PubMed ID: 38385853
    [No Abstract]   [Full Text] [Related]  

  • 13. Vertex CF data wow Wall Street.
    Nat Biotechnol; 2017 Sep; 35(9):807. PubMed ID: 28898228
    [No Abstract]   [Full Text] [Related]  

  • 14. [Causal therapy is available].
    Meißner T
    MMW Fortschr Med; 2016 Jun; 158(12):74. PubMed ID: 27324018
    [No Abstract]   [Full Text] [Related]  

  • 15. Lumacaftor-ivacaftor (Orkambi) for cystic fibrosis: behind the 'breakthrough'.
    Mayer M
    Evid Based Med; 2016 Jun; 21(3):83-6. PubMed ID: 26718821
    [No Abstract]   [Full Text] [Related]  

  • 16. [Combined administration of lumacaftor and ivacaftor as a causal therapeutic approach].
    Desch M
    Med Monatsschr Pharm; 2016 Jan; 39(1):42-4. PubMed ID: 26975180
    [No Abstract]   [Full Text] [Related]  

  • 17. Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm?
    Jones AM; Barry PJ
    Thorax; 2015 Jul; 70(7):615-6. PubMed ID: 26071414
    [No Abstract]   [Full Text] [Related]  

  • 18. A combination therapy for cystic fibrosis.
    Brodsky JL; Frizzell RA
    Cell; 2015 Sep; 163(1):17. PubMed ID: 26406363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cystic Fibrosis: The Dawn of a New Therapeutic Era.
    Heltshe SL; Cogen J; Ramos KJ; Goss CH
    Am J Respir Crit Care Med; 2017 Apr; 195(8):979-984. PubMed ID: 27710011
    [No Abstract]   [Full Text] [Related]  

  • 20. Negotiations between the NHS and Vertex on access to lumacaftor and ivacaftor become protracted.
    Burki TK
    Lancet Respir Med; 2019 Sep; 7(9):739-740. PubMed ID: 31353281
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.